Screener
Bioventus BVS Pain Treatments — Total Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Bioventus’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:43 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001665988-26-000042
| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
|---|---|---|---|---|
| Net sales | $153,208 | $147,660 | $285,297 | $271,536 |
| Cost of sales (including depreciation and amortization of $9,893, $10,603, $19,980 and $20,868, respectively) | 47,542 | 45,570 | 88,862 | 86,390 |
| Gross profit | 105,666 | 102,090 | 196,435 | 185,146 |
| Selling, general and administrative expense | 82,740 | 79,110 | 161,065 | 152,612 |
| Research and development expense | 3,173 | 3,172 | 5,640 | 6,183 |
| Restructuring costs | (415) | — | 39 | — |
| Depreciation and amortization | 1,041 | 1,439 | 2,148 | 3,032 |
| Loss on disposals | — | 1 | — | 82 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bioventus's pain treatments — total net sales?
- Bioventus (BVS) reported pain treatments — total net sales of $81.75M in Q2 2026.
- How has Bioventus's pain treatments — total net sales changed year-over-year?
- Bioventus's pain treatments — total net sales increased by 11.5% year-over-year, from $73.31M to $81.75M.
- What is the long-term trend for Bioventus's pain treatments — total net sales?
- Over 4 years (2021 to 2025), Bioventus's pain treatments — total net sales has grown at a 5.9% compound annual growth rate (CAGR), from $221.61M to $279.06M.
- What does pain treatments — total net sales mean?
- This metric represents the total revenue generated from the sale of medical products and therapeutic solutions specifically designed for pain management and orthopedic recovery. It reflects the commercial performance and market adoption of the company's specialized portfolio within the pain treatment segment. Tracking this figure helps investors assess the growth trajectory and demand for the company's core therapeutic offerings.
Ask your AI about Bioventus's pain treatments — total net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude